Although the process of finding a partner has been slower than anticipated, the company has maintained that they are focusing most of their attention on their ImmunoPulse platform (the partnering is for NeoPulse). They believe that ImmunoPulse is where the future value of the company is.
It appears from the recent developments that ONCS is not going to enter into a partnership any time soon. The company is well funded for 2013, and the company has a strong reserve of shares with whic it is able to raise capital for 2014 (and dilute existing holders in the process). But dilution should not matter if the clinical results continue to improve. I was hoping for a partnership, as I am sure many of us were, but it does not appear to be on the horizon. If trials go well, PPS will increase regardless of dilution. I figure most Longs feel that the trials will go well, or we would not be holding on for so long. I think that a PPS base of .20 is pretty safe and the PPS may trend higher by 2 or 3 cents in 2013. Trysson is long.